Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 1, 2024Journal of Oncology Pharmacy PracticeOpen Access

Safety outcomes of teclistamab accelerated dose escalation

View Full Paper
Ask AI
Bookmark
Share

Authors

YKYumena KawasakiASAaron Paul SteeleARAaron S. Rosenberg

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Kawasaki et al. (2024) studied this question.

synapsesocial.com/papers/68e5dd8fb6db643587572e04https://doi.org/10.1177/10781552241268429
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies2024 · 59 citations
  2. 2<i>“Fast but not so furious”</i>: A condensed step‐up dosing schedule of teclistamab for relapsed/refractory multiple myeloma2024 · 3 citations
  3. 3Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma.2024 · 86 citations
  4. 4Teclistamab-associated adverse events: a disproportionality analysis of the FDA adverse event reporting system2026
  5. 5Real-world outcomes of teclistamab for the treatment of relapsed/refractory multiple myeloma at UC San Diego Health: A single-institution experience.2024 · 5 citations